Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sominex Composto is a traditional herbal medicinal product developed and manufactured by EMS S/A in Brazil. It is a fixed-dose combination of three plant extracts: *Valeriana officinalis* (Valerian), *Crataegus oxyacantha* (Hawthorn), and *Passiflora incarnata* (Passionflower). The product is indicated as a mild sedative and for the treatment of sleep disturbances (insomnia) associated with anxiety. Its mechanism of action involves the synergistic modulation of the GABAergic system, primarily through interactions with Gamma-aminobutyric acid type A (GABA-A) and type B (GABA-B) receptors. Valerian and Passionflower are known to enhance GABAergic signaling, leading to reduced cerebral activity and sleep induction, while Hawthorn contributes relaxing properties that help alleviate anxiety symptoms. It is formulated as an oral small molecule product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sominex Composto.